Blog

The Pharmaceutical Patent Analyst, the Future Science Group journal for all matters related to intellectual property in the life sciences, has been publishing H.M. Pharma Consultancy's Patent Highlights since the journal's inception in 2012, and this will continue in 2018.
We are delighted to announce that MedChemNet, the premiere network for the medicinal chemistry community where researchers sh...

Along the lines that have been discussed in a recent Frontiers short paper, here is a list of our patent discussions in the December 2017 drug repurposing special issue of ASSAY and Drug Development Technologies:
WO/2017/059389 (Kythera Biopharmaceuticals, USA): Statins as an alternative to liposuction and cryolipolysis
WO/2017/060308 (AB Science, France): Masitinib switches to human use
WO/201...

CRC Press has published a new book, „Drug Repositioning – Approaches and Applications for Neurotherapeutics,“ edited by Joel Dudley (Mount Sinai School of Medicine, New York) and Laura Berliocchi (Magna Graecia University, Catanzaro, Italy). Over forty scientists from academia and industry have contributed to this richly referenced 313-page print book (ISBN 9781482220834), which is also available ...

Thanks to all who have attended the 6th annual Drug Repositioning, Repurposing and Rescue Conference in Chicago on June 28 & 29. We had two excellent days of presentations, formal discussions, and informal meetings on the sidelines. Also, the well-established close collaboration with Cures Within Reach has been fruitful once more.
The potential of this annual event, organized by Arrowhead, ...

If you follow our discussions of patent documents claiming radically new uses for known compounds, published in the issues that ASSAY and Drug Development Technologies dedicates to drug repurposing, you might think that there is a lot of patenting activity going on in this field – indicative of broad commercial interest.
Actually, there is significantly more out there. However, the space we can a...

No life science patents, congresses or corporate matters this time. This post goes beyond. It should affect your choice of flights to Arrowhead’s annual Drug Repurposing Conference in June.
Imagine you have booked a table at a Chicago restaurant. To get the reservation, you had to pay in advance. While you are waiting for your meal, you are suddenly ordered to give up your table: somebody from ...

The kind people at Mary Ann Liebert, Inc. Publishers have accelerated publication of ASSAY and Drug Development Technologies’ summer special issue: we got sufficient good manuscripts to warrant that. And lo!, this allows us to publish discussions of selected drug repurposing patent applications in a very timely manner. Once again, incredible pharmacological creativity from around the world! Here i...

Today the UK government has finally activated Article 50 of the Lisbon Treaty, officially declaring what had been decided nine months ago: they are leaving the European Union for good, by April 2019 at the latest – deal or no deal.
That the European Medicines Agency would have to move from its Canary Wharf offices in London to the Continent had been obvious as soon as the Brexit vote was announ...

Winter is coming…. And that means that ASSAY and Drug Development Technologies will publish another special issue on drug repurposing. Here are the highlights of the PCT patent applications from Q2 and Q3/2016 that will be discussed.
X-Ray Contrast Agents for Ebola (WO/2016/054658, 3e Therapeutics Corp.)
A Heart Failure Drug for Myopathies and Respiratory ALS Complications (WO/2016/059287,...

H.M. Pharma Consultancy will present at the·B·Debate conference, Drug Repurposing for Rare Diseases. The Cure for the 21st Century, to be held in Barcelona on November 17 and 18, 2016. This event, jointly organized by Barcelona's innovative health ecosystem, biocat and "la Caixa" Foundation, with Barcelona Science Park (PCB) and Hospital Sant Joan de Déu (HSJD), offers an interdisciplinary forum w...